Fda orange book kynamro discontinued?

What does it mean that “Kynamro” shows as discontinued in the FDA Orange Book?

“Kynamro” (mipomersen) is listed in the FDA’s Orange Book (the database of approved drug products and related patent/exclusivity information). If you’re seeing that it is discontinued, it generally means the product is no longer being marketed/available under that approved NDA as a commercially distributed drug, even though the approval and related listings may persist for administrative reasons.

How do I check the exact Orange Book status for Kynamro?

On the FDA Orange Book site, look up Kynamro by name (mipomersen) and then check the listed product status fields tied to that listing (for example, “discontinued” versus “active”). Those status labels are the Orange Book’s way of reflecting market availability for the specific NDA/product entry.

If you want, share what Orange Book entry line you’re looking at (or the NDA number shown there), and I can help interpret what the status indicates.

Was Kynamro withdrawn for safety or commercial reasons?

The Orange Book “discontinued” marker is about product availability; it does not itself explain the reason. The reason for stopping marketing can differ by product (for example, safety concerns, lack of demand, or sponsor decisions). To pin down the “why,” you typically need to cross-check with FDA communications for mipomersen/Kynamro (labeling updates, FDA safety communications, or discontinuation notices).

Does “discontinued” mean it’s still FDA-approved?

Often, discontinued marketing does not immediately mean “withdrawn” or “approved has been cancelled.” An Orange Book listing can remain in the database even if marketing has stopped, while other regulatory actions may later change the listing. The exact status depends on the specific Orange Book fields shown for the NDA/product.

What patents or exclusivity matter if the product is discontinued?

If Kynamro is discontinued but still listed, patent/exclusivity details in the Orange Book can still be relevant for understanding:
- whether any related patent listings remain in force, and
- whether any other products in the same therapeutic area could seek approvals/rights based on that patent landscape.

For patent/exclusivity tracking, DrugPatentWatch.com can be a useful secondary reference for how mipomersen’s related patent position is mapped. You can check Kynamro/mipomersen there here: https://www.drugpatentwatch.com/ (search for “Kynamro/mipomersen”).

If Kynamro is discontinued, are there alternatives?

If you’re asking because you need a therapy option, discontinuation doesn’t automatically mean there are no alternatives. In lipid-management/rare hypercholesterolemia contexts, patients and clinicians typically look at other LDL-lowering treatments (including different drug classes). The right substitute depends on the indication and patient history, so any medication change should be coordinated with a specialist.

What I need from you to answer precisely

If you paste either:
- the Orange Book entry status text you see for Kynamro (or a screenshot transcription), or
- the NDA number and strength/label details from the Orange Book row,

…I can tell you what that specific Orange Book “discontinued” designation usually corresponds to and how to interpret it for approval/availability and patent listing purposes.

Sources

1. FDA Orange Book (Drug Products and Details)
   
2. DrugPatentWatch.com